Perspectives on the development of neutralizing antibodies against SARS-CoV-2

SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angiotensin-converting enzyme 2 (ACE2). Therefore, the receptor binding domain (RBD) of the S protein is the primary target for neutralizing antibodies. Selection of broad-neutralizing antibodies against SARS-CoV-2 and SA...

Descripción completa

Detalles Bibliográficos
Autor principal: Ho, Mitchell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291920/
https://www.ncbi.nlm.nih.gov/pubmed/32566896
http://dx.doi.org/10.1093/abt/tbaa009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291920/
https://www.ncbi.nlm.nih.gov/pubmed/32566896
http://dx.doi.org/10.1093/abt/tbaa009

Ejemplares similares